Boston's resTORbio Sets Terms for $85M IPO Post author:Sam Post published:January 16, 2018 Post category:BioPharma resTORbio is developing novel therapies to improve immune function in the elderly. Source: BioSpace You Might Also Like Boston-Based Biotech Inks Immuno-Oncology Pact With Seattle Genetics February 8, 2018 Mis-Matched Expectations With Celgene, Ionis October 24, 2017 Race Heats Up As Mallinckrodt Gets Bids August 8, 2017
